Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 12/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.35 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1771449 | 0.82 | RORC (0.35) | MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL16205092 | 0.81 | TDP1 (0.51) | KMT2AALDH1A1 | |
| SCHEMBL3756015 | 0.80 | MEN1 (0.44) | CYP2C19HTR7HTR1ADRD2HTR2A | |
| SCHEMBL14760451 | 0.79 | KMT2A (0.37) | FKBP1ACYP2C19HTR7HTR1ADRD2 | |
| SCHEMBL13721711 | 0.78 | CYP2C19 (0.39) | FKBP1ACYP2C19HTR7HTR1ADRD2 | |
| SCHEMBL515759 | 0.78 | ALDH1A1 (0.43) | CYP2C19KMT2AALDH1A1ENPP3ENPP1 | |
| SCHEMBL13157302 | 0.78 | MEN1 (0.38) | FKBP1AMEN1KMT2AALDH1A1 | |
| SCHEMBL12556596 | 0.77 | MEN1 (0.38) | FKBP1AMEN1KMT2AALDH1A1 | |
| SCHEMBL16205181 | 0.77 | MEN1 (0.38) | FKBP1AMEN1KMT2AALDH1A1 | |
| SCHEMBL14760462 | 0.76 | KMT2A (0.41) | CYP2C19HTR7HTR1ADRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877960-B2 | Fluoroalkanesulfonic acid ammonium salts and method for producing same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2014-11-04 | — | — | US | disclosed |
| US-20110313190-A1 | Fluoroalkanesulfonic Acid Ammonium Salts and Method for Producing Same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313190-A1 | Fluoroalkanesulfonic Acid Ammonium Salts and Method for Producing Same | PFAS, ARSA, NOTUM | FKBP1A 4362/4885CYP2C19 1864/4885HTR7 3207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.